中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

714 records (took 0.043 seconds)

    ATTENUATED ENTEROHEMORRHAGIC E.COLI-BASED VACCINE VECTOR AND METHODS RELATING THERETO
    111.
    发明申请
    ATTENUATED ENTEROHEMORRHAGIC E.COLI-BASED VACCINE VECTOR AND METHODS RELATING THERETO 有权
    基于大肠杆菌的肠易激综合疫苗向量及其相关方法

    公开(公告)号：US20120093870A1

    公开(公告)日：2012-04-19

    申请号：US13378116

    申请日：2010-06-30

    Applicant: Edgar C. Boedeker ,  Isaac Wyatt Byrd

    Inventor： Edgar C. Boedeker ,  Isaac Wyatt Byrd

    IPC: A61K39/108 ,  A61P31/04 ,  A61P37/04

    CPC classification number: A61K39/0258 ,  A61K2039/522 ,  A61K2039/523 ,  Y02A50/474

    Abstract: An attenuated enterohemorrhagic E. coli-based vaccine vector is disclosed. Enterotoxigenic E. coli colonization factor antigen 1 and the B subunit of E. coli heat labile toxin have been expressed in the attenuated enterohemorrhagic E. coli vector strain. Immunized animals are further protected against lethal and non lethal challenges with the enterotoxigenic E. coli strain. Immunization of mice with the vaccine construct induces mucosal antibody against both antigens, establishing the attenuated E. coli vector strain as a generally useful vector for presenting one or more antigens to a subject in a vaccine.

    Abstract translation: 公开了一种减毒的肠出血性大肠杆菌疫苗载体。 肠毒素大肠杆菌定殖因子抗原1和大肠杆菌热不稳定毒素的B亚基已经在减毒的肠出血性大肠杆菌载体菌株中表达。 进一步保护免疫的动物免受肠致毒性大肠杆菌菌株的致死和非致命性挑战。 用疫苗构建体免疫小鼠诱导针对两种抗原的粘膜抗体，建立减毒的大肠杆菌载体菌株作为向疫苗中的受试者呈递一种或多种抗原的通常有用的载体。

    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER
    114.
    发明申请
    METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER 有权
    用于治疗癌症的方法和相关组合物

    公开(公告)号：US20110224141A1

    公开(公告)日：2011-09-15

    申请号：US12990334

    申请日：2009-06-05

    Applicant: Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

    Inventor： Todd A. Thompson ,  Debra Mackenzie ,  Tudor I. Oprea ,  Larry A. Sklar ,  Bruce S. Edwards ,  Mark Haynes

    IPC: A61K31/454 ,  A61K31/496 ,  A61K38/08 ,  A61K31/56 ,  A61P35/00

    CPC classification number: A61K31/437 ,  A61K31/135 ,  A61K31/165 ,  A61K31/445 ,  A61K45/06 ,  A61N5/10

    Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed.

    Abstract translation: 治疗和/或预防癌症的方法包括在癌细胞中引起增加的细胞内颗粒度的给药剂，至少足以抑制这些细胞增殖的量，优选以足以导致癌细胞死亡的量。 该方法特别涉及难治性癌症，特别是激素难治性前列腺癌。 所鉴定的试剂导致癌细胞中的细胞内颗粒度增加，并且将粘附的癌细胞转化为非贴壁癌细胞，导致癌细胞死亡。 使用本发明，癌细胞在相对低的药物浓度下经历增加的细胞内粒度，同时也抑制细胞增殖。 增加的浓度导致粘附的癌细胞转化为非粘附的癌细胞，然后转移到细胞死亡。 虽然癌细胞降解和死亡的确切机制尚未完全了解，但治疗的癌细胞（包括难治性前列腺癌细胞）通过自噬机制给予细胞死亡的指示。 还公开了与目前公开的方法相关的药物组合物。

    Thin-walled structures
    117.
    发明授权
    Thin-walled structures 有权
    薄壁结构

    公开(公告)号：US07968359B2

    公开(公告)日：2011-06-28

    申请号：US12237469

    申请日：2008-09-25

    Applicant: Stephen D. Hersee

    Inventor： Stephen D. Hersee

    IPC: H01L21/00

    CPC classification number: C30B29/60 ,  B82Y20/00 ,  B82Y30/00 ,  H01L21/0237 ,  H01L21/02458 ,  H01L21/0254 ,  H01L21/02603 ,  H01L21/02606 ,  H01L21/0262 ,  H01L21/02636 ,  H01L21/02639 ,  H01L31/0304 ,  H01L31/035236 ,  H01L31/184 ,  H01L33/18 ,  H01L33/24 ,  H01S5/10 ,  H01S5/18 ,  H01S5/34 ,  H01S5/3428 ,  Y02E10/544 ,  Y10S977/816

    Abstract: Various embodiments provide thin-walled structures and methodologies for their formation. In one embodiment, the thin-walled structure can be formed by disposing a semiconductor material in a patterned aperture using a selective growth mask that includes a plurality of patterned apertures, followed by a continuous growth of the semiconductor material using a pulsed growth mode. The patterned aperture can include at least one lateral dimension that is small enough to allow a threading defect termination at sidewall(s) of the formed thin-walled structure. In addition, high-quality III-N substrate structures and core-shell MQW active structures can be formed from the thin-walled structures for use in devices like light emitting diodes (LEDs), lasers, or high electron mobility transistors (HEMTs).

    Abstract translation: 各种实施例提供了用于其形成的薄壁结构和方法。 在一个实施例中，薄壁结构可以通过使用包括多个图案化孔的选择性生长掩模将半导体材料设置在图案化孔中形成，随后使用脉冲生长模式连续生长半导体材料。 图案化的孔可以包括至少一个足够小的横向尺寸，以允许在形成的薄壁结构的侧壁处的穿线缺陷终止。 此外，可以从用于诸如发光二极管（LED），激光器或高电子迁移率晶体管（HEMT）的器件中的薄壁结构形成高质量的III-N衬底结构和核 - 壳MQW有源结构。

    SELF-ALIGNED SPATIAL FREQUENCY DOUBLING
    118.
    发明申请
    SELF-ALIGNED SPATIAL FREQUENCY DOUBLING 有权
    自对准空间频率双重

    公开(公告)号：US20110127235A1

    公开(公告)日：2011-06-02

    申请号：US13022740

    申请日：2011-02-08

    Applicant: Steven R.J. Brueck ,  Andrew Frauenglass ,  Alexander K. Raub ,  Dong Li

    Inventor： Steven R.J. Brueck ,  Andrew Frauenglass ,  Alexander K. Raub ,  Dong Li

    IPC: B32B38/06

    CPC classification number: H01L21/3086 ,  H01L21/0337 ,  H01L21/0338 ,  H01L21/3088 ,  H01L21/31144

    Abstract: In accordance with the invention, there are methods for self-aligned spatial frequency doubling in one dimension and also in two dimension. The method for self-aligned spatial frequency doubling in one dimension can include forming a film stack over a substrate, wherein the film stack comprises a photoresist layer and forming a one-dimensional periodic first pattern having a first pitch p on the photoresist layer using an optical exposure, wherein the first pitch p is at least smaller than twice the bandpass limit for optical exposures. The method can also include forming a second pattern using the first pattern by nonlinear processing steps, wherein the second pattern has a second pitch p2=p/2.

    Abstract translation: 根据本发明，在一维和二维中存在自对准空间倍频的方法。 在一个维度中自对准空间倍频的方法可以包括在衬底上形成膜堆叠，其中膜堆叠包括光致抗蚀剂层并且在光刻胶层上形成具有第一间距p的一维周期性第一图案，使用 光学曝光，其中第一间距p至少小于光学曝光的带通极限的两倍。 该方法还可以包括通过非线性处理步骤使用第一图案形成第二图案，其中第二图案具有第二间距p2 = p / 2。

    Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition
    119.
    发明授权
    Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition 有权
    通过等离子体辅助原子层沉积制备纳米多孔低k ILD的致密，共形，超薄盖层的方法

    公开(公告)号：US07947579B2

    公开(公告)日：2011-05-24

    申请号：US11673190

    申请日：2007-02-09

    Applicant: Ying-Bing Jiang ,  Joseph L. Cecchi ,  C. Jeffrey Brinker

    Inventor： Ying-Bing Jiang ,  Joseph L. Cecchi ,  C. Jeffrey Brinker

    IPC: H01L21/4763

    CPC classification number: A61K45/06 ,  A61K31/167 ,  A61K31/7048 ,  H01L21/76814 ,  H01L21/76826 ,  H01L21/76831 ,  Y10S977/89 ,  A61K2300/00

    Abstract: Barrier layers and methods for forming barrier layers on a porous layer are provided. The methods can include chemically adsorbing a plurality of first molecules on a surface of the porous layer in a chamber and forming a first layer of the first molecules on the surface of the porous layer. A plasma can then be used to react a plurality of second molecules with the first layer of first molecules to form a first layer of a barrier layer. The barrier layers can seal the pores of the porous material, function as a diffusion barrier, be conformal, and/or have a negligible impact on the overall ILD k value of the porous material.

    Abstract translation: 提供了阻挡层和在多孔层上形成阻挡层的方法。 所述方法可以包括在多孔层的多孔层的表面上化学吸附多个第一分子并在多孔层的表面上形成第一分子的第一层。 然后可以使用等离子体来使多个第二分子与第一分子的第一层反应以形成阻挡层的第一层。 阻挡层可以密封多孔材料的孔，用作扩散阻挡层，保形，和/或对多孔材料的整体ILD k值具有可忽略的影响。

    Human kunitz-type inhibitor with enhanced antifibrinolytic activity
    120.
    发明授权
    Human kunitz-type inhibitor with enhanced antifibrinolytic activity 有权
    具有增强抗纤维蛋白溶解活性的人类kunitz型抑制剂

    公开(公告)号：US07910550B2

    公开(公告)日：2011-03-22

    申请号：US12286933

    申请日：2008-10-03

    Applicant: Walter Kisiel ,  Hitendra S. Chand

    Inventor： Walter Kisiel ,  Hitendra S. Chand

    IPC: A61K38/00

    CPC classification number: C07K14/8114 ,  A61K38/00

    Abstract: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2). In another aspect, methods of treating a subject afflicted with cancer or a precancerous condition are described. Generally, the method includes administering to a subject in need of treatment an effective amount of a polypeptide. In some embodiments, the polypeptide comprises a KD1 domain of human TFPI-2. In some embodiments, the polypeptide comprises human TFPI-2, itself. In certain embodiments, the polypeptide is administered in an amount effective to induce apoptosis in tumor cells.

    Abstract translation: 具有增强的抗纤维蛋白溶解活性的人Kunitz型抑制剂多肽，制备方法和使用方法。 新型多肽在结构上类似于人组织因子途径抑制剂-2（TFPI-2）的KD1结构域。 另一方面，描述了治疗患有癌症或癌前病症的受试者的方法。 通常，该方法包括向需要治疗的受试者施用有效量的多肽。 在一些实施方案中，多肽包含人TFPI-2的KD1结构域。 在一些实施方案中，多肽本身包含人TFPI-2。 在某些实施方案中，以有效诱导肿瘤细胞凋亡的量施用多肽。

Patent Agency Ranking